Quavonlimab clinical trials
Also written MK-1308.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses quavonlimab has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Lenvatinib (2) · Vibostolimab (1) · Tretinoin (1) · Favezelimab (1) · Pembrolizumab/Quavonlimab MK-1308A (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses quavonlimab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04305041Written as QuavonlimabReport a problem
- A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)CompletedPhase 2Merck Sharp & Dohme LLCNCT03516981Written as QuavonlimabReport a problem
- Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT03179436Written as QuavonlimabReport a problem
Tested in a combination · 3 — another drug in the study is under test too
- Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04305041Written as QuavonlimabReport a problem
- A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)CompletedPhase 2Merck Sharp & Dohme LLCNCT03516981Written as QuavonlimabReport a problem
- Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT03179436Written as QuavonlimabReport a problem
Codes
What other systems call quavonlimab · ClinicalTrials.gg INT016668
- UNII (FDA) GG0AN49Y59QUAVONLIMABOne source FDA
- NCI Thesaurus C150679QuavonlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | GG0AN49Y59 | QUAVONLIMAB | One source FDA |
| NCI Thesaurus | C150679 | Quavonlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.